Cyclic nucleotide phosphodiesterase 3 (PDE3)

Cyclic nucleotide phosphodiesterase 3 (PDE3) is an enzyme that hydrolyzes cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP), two critical intracellular messengers implicated in a wide range of physiological processes such as signal transduction, regulation of myocardial contractility, vascular smooth muscle relaxation, platelet aggregation, proliferation, and apoptosis. PDE3 exists as two main isoforms in humans: PDE3A, predominantly expressed in cardiovascular tissues (heart, vascular smooth muscle, platelets), and PDE3B, found mainly in adipose tissue, liver, and some epithelial tissues[1][5]. Therapeutic inhibition of PDE3 increases intracellular cAMP and cGMP concentrations, leading to effects like vasodilation, positive inotropy, inhibition of platelet aggregation, and metabolic modulation. PDE3 isoenzymes are established drug targets for conditions including heart failure, intermittent claudication, and thrombocytopenia. Common drugs targeting PDE3 include milrinone, cilostazol, amrinone, and enoximone[2][5][8]. However, chronic use—especially in heart failure—may increase the risk of fatal arrhythmias and adverse cardiovascular events, limiting their long-term application[1][4]. Emerging research includes using PDE3 as a potential biomarker for disease-related signaling alterations and exploring novel regulatory mechanisms beyond direct inhibition[2].

Other names

Phosphodiesterase 3PDE3APDE3BCyclic nucleotide phosphodiesterase type 33′,5′-cyclic nucleotide phosphodiesterase class III

Catalytic inhibition (PDE3 inhibitors block the hydrolysis of cAMP/cGMP, raising their intracellular levels) Modulation of compartmentalization or post-translational modification (emerging therapeutic strategies)